QR code

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study

ObjectivesPembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%. This study aimed to figure out...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Ya Chen, Yanan Wang, Zhengyu Yang, Minjuan Hu, Yanwei Zhang, Fangfei Qian, Wei Zhang, Bo Zhang, Baohui Han
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2021-06-01
Reeks:Frontiers in Oncology
Onderwerpen:
non small cell lung cancer
pembrolizumab
chemotherapy
immunotherapy
programed cell death protein 1 (PD-1)
Online toegang:https://www.frontiersin.org/articles/10.3389/fonc.2021.691519/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items